Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rang in aandelen #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aandeelprijs
$9.60
Laatst gesynchroniseerd: 2025-05-21
Marktkapitalisatie
$1.08B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Categorie

Winst voor OptiNose, Inc. (OPTN)
Winst in Mar 2025 TTM: $-29.89M
Volgens de meest recente financiële verslagen van OptiNose, Inc. bedraagt de huidige winst van het bedrijf $-29.89M. In 2023 behaalde het bedrijf een winst van $-35.48M, een stijging ten opzichte van de winst van 2022, die $-74.83M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van OptiNose, Inc. van 2015 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%
Winst van vergelijkbare bedrijven of concurrenten